Company profile
ASCENDIS PHARMA A/S
NASDAQ:ASNDBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SKYTROFA | approved | — | 0 | — |
| SKYTROFA | approved | — | 0 | — |
| YORVIPATH | approved | — | 0 | — |
| YUVIWEL | approved | — | 3 | approved |
| ACP-001 | phase2 | — | 3 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06732895 | phase2 | recruiting | 2024-12-10 | 2027-08-01 | Ascendis Pharma A/S | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. |
| NCT05598320 | phase2_3 | completed | 2023-03-03 | 2024-08-09 | Ascendis Pharma Growth Disorders A/S | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia |
| NCT06079398 | phase2 | recruiting | 2024-01-23 | 2027-12-01 | Ascendis Pharma A/S | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia |
| NCT05929807 | phase2_3 | enrolling_by_invitation | 2023-06-21 | 2039-01-01 | Ascendis Pharma Growth Disorders A/S | A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia |
| NCT04085523 | phase2 | completed | 2020-06-24 | 2022-09-27 | Ascendis Pharma A/S | A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia |
FDA applications (3)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 219164 | 2026-02-27 | NDA | ASCENDIS PHARMA GROWTH DISORDERS AS | |||||
Loading… | ||||||||
| NDA 216490 | 2024-08-09 | NDA | ASCENDIS PHARMA BONE DISEASES AS | |||||
Loading… | ||||||||
| BLA 761177 | 2021-08-25 | BLA | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S | |||||
Loading… | ||||||||